Oppositional Defiant Disorder Completed Phase 1 Trials for Brexpiprazole (DB09128)

Also known as: Conduct Disorder / Disruptive Behavior Disorders / Disruptive behaviour disorder / Disruptive Behavior Disorder / Conduct Disorders / Behavior Disorder, Disruptive / Conduct behavior disorder / Conduct behaviour disorder / Unspecified disturbance of conduct

IndicationStatusPhase
DBCOND0032311 (Oppositional Defiant Disorder)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03292848Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System DisordersTreatment